Concert Pharmaceuticals Inc

NASDAQ:CNCE   3:59:56 PM EDT
4.55
+0.28 (+6.56%)
Products, Regulatory, Earnings Announcements

Concert Pharmaceuticals Reports Positive Topline Results For First CTP-543 Phase 3 Clinical Trial

Published: 05/23/2022 11:53 GMT
Concert Pharmaceuticals Inc (CNCE) - Concert Pharmaceuticals Reports Positive Topline Results for First Ctp-543 Phase 3 Clinical Trial in Alopecia Areata.
Concert Pharmaceuticals Inc - Hrive-aa1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses.
Concert Pharmaceuticals Inc - Topline Data From Second Phase 3 Trial, Thrive-aa2, Expected Q3 of 2022.
Concert Pharmaceuticals Inc - Statistically Significant Hair Regrowth Observed As Early As Eight Weeks.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.89

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.83

More details on our Analysts Page.